189 related articles for article (PubMed ID: 21605820)
1. Objective scoring systems for disease activity in autoimmune bullous disease.
Sebaratnam DF; Murrell DF
Dermatol Clin; 2011 Jul; 29(3):515-20, xi. PubMed ID: 21605820
[TBL] [Abstract][Full Text] [Related]
2. Development of an Excel® spreadsheet to document disease activity in autoimmune bullous disease.
Sebaratnam DF; Venugopa SS; Murrell DF
Acta Dermatovenerol Croat; 2013; 21(3):207-8. PubMed ID: 24183229
[No Abstract] [Full Text] [Related]
3. Severity score indexes for blistering diseases.
Daniel BS; Hertl M; Werth VP; Eming R; Murrell DF
Clin Dermatol; 2012; 30(1):108-13. PubMed ID: 22137234
[TBL] [Abstract][Full Text] [Related]
4. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.
Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF
JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444
[TBL] [Abstract][Full Text] [Related]
5. Outcome measures for autoimmune blistering diseases.
Zhao CY; Murrell DF
J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
[TBL] [Abstract][Full Text] [Related]
6. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.
Pfütze M; Niedermeier A; Hertl M; Eming R
Eur J Dermatol; 2007; 17(1):4-11. PubMed ID: 17324820
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune bullous dermatoses: a review.
Patrício P; Ferreira C; Gomes MM; Filipe P
Ann N Y Acad Sci; 2009 Sep; 1173():203-10. PubMed ID: 19758152
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of infiltrating cells in the lesional skin of the autoimmune diseases-pemphigus, pemphigoid, and lupus erythematosus].
Hayakawa K
Nihon Hifuka Gakkai Zasshi; 1988 Sep; 98(10):1023-8. PubMed ID: 3065535
[No Abstract] [Full Text] [Related]
9. Diagnosis of autoimmune bullous skin diseases.
Zillikens D
Clin Lab; 2008; 54(11-12):491-503. PubMed ID: 19216255
[TBL] [Abstract][Full Text] [Related]
10. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires.
Kalinska-Bienias A; Jakubowska B; Kowalewski C; Murrell DF; Wozniak K
Adv Med Sci; 2017 Mar; 62(1):92-96. PubMed ID: 28208086
[TBL] [Abstract][Full Text] [Related]
11. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.
Bertram F; Bröcker EB; Zillikens D; Schmidt E
J Dtsch Dermatol Ges; 2009 May; 7(5):434-40. PubMed ID: 19170813
[TBL] [Abstract][Full Text] [Related]
12. Immunopathology of pemphigus vulgaris, bullous pemphigoid and related bullous dermatoses.
Patel HP; Anhalt GJ; Provost TT; Diaz LA
Clin Immunol Rev; 1983-1984; 2(2):157-86. PubMed ID: 6370527
[No Abstract] [Full Text] [Related]
13. Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses.
Iwata H; Bieber K; Hirose M; Ludwig RJ
Curr Pharm Des; 2015; 21(18):2422-39. PubMed ID: 25777758
[TBL] [Abstract][Full Text] [Related]
14. [Immunopathology of autoimmune bullous dermatoses].
Prost C
Ann Pathol; 1992; 12(4-5):276-83. PubMed ID: 1466684
[No Abstract] [Full Text] [Related]
15. Direct and indirect immunofluorescence for the diagnosis of bullous autoimmune diseases.
Pohla-Gubo G; Hintner H
Dermatol Clin; 2011 Jul; 29(3):365-72, vii. PubMed ID: 21605801
[TBL] [Abstract][Full Text] [Related]
16. Loss of Work Productivity and Quality of Life in Patients With Autoimmune Bullous Dermatoses.
Heelan K; Hitzig SL; Knowles S; Drucker AM; Mittmann N; Walsh S; Shear NH
J Cutan Med Surg; 2015; 19(6):546-54. PubMed ID: 25888597
[TBL] [Abstract][Full Text] [Related]
17. Nail involvement in autoimmune bullous disorders.
Tosti A; André M; Murrell DF
Dermatol Clin; 2011 Jul; 29(3):511-3, xi. PubMed ID: 21605819
[TBL] [Abstract][Full Text] [Related]
18. [Relevance of histological examination in the diagnosis of autoimmune bullous dermatoses].
Rose C; Bröcker EB; Zillikens D
J Dtsch Dermatol Ges; 2004 Feb; 2(2):96-104. PubMed ID: 16279243
[TBL] [Abstract][Full Text] [Related]
19. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.
Tjokrowidjaja A; Daniel BS; Frew JW; Sebaratnam DF; Hanna AM; Chee S; Dermawan A; Wang CQ; Lim C; Venugopal SS; Rhodes LM; Welsh B; Nijsten T; Murrell DF
Br J Dermatol; 2013 Nov; 169(5):1000-6. PubMed ID: 24102329
[TBL] [Abstract][Full Text] [Related]
20. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
Boulard C; Duvert Lehembre S; Picard-Dahan C; Kern JS; Zambruno G; Feliciani C; Marinovic B; Vabres P; Borradori L; Prost-Squarcioni C; Labeille B; Richard MA; Ingen-Housz-Oro S; Houivet E; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P;
Br J Dermatol; 2016 Jul; 175(1):142-9. PubMed ID: 26800395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
